These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
463 related articles for article (PubMed ID: 19137597)
1. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis. Santos RP; Prestidge CB; Brown ME; Urbancyzk B; Murphey DK; Salvatore CM; Jafri HS; McCracken GH; Ahmad N; Sanchez PJ; Siegel JD Pediatr Pulmonol; 2009 Feb; 44(2):148-54. PubMed ID: 19137597 [TBL] [Abstract][Full Text] [Related]
2. Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis. Saralaya D; Peckham DG; Hulme B; Tobin CM; Denton M; Conway S; Etherington C J Antimicrob Chemother; 2004 Feb; 53(2):325-8. PubMed ID: 14729733 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Boak LM; Li J; Rayner CR; Nation RL Antimicrob Agents Chemother; 2007 Apr; 51(4):1287-92. PubMed ID: 17242144 [TBL] [Abstract][Full Text] [Related]
4. Linezolid pharmacokinetics in pediatric patients: an overview. Jungbluth GL; Welshman IR; Hopkins NK Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S153-7. PubMed ID: 14520140 [TBL] [Abstract][Full Text] [Related]
5. Experience with linezolid therapy in children with osteoarticular infections. Chen CJ; Chiu CH; Lin TY; Lee ZL; Yang WE; Huang YC Pediatr Infect Dis J; 2007 Nov; 26(11):985-8. PubMed ID: 17984803 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and tolerance of linezolid for meticillin-resistant Staphylococcus aureus mediastinitis in paediatric patients. Kosaka T; Kokufu T; Shime N; Sugioka N; Kato R; Hamaoka K; Fujita N Int J Antimicrob Agents; 2009 Apr; 33(4):368-70. PubMed ID: 19097868 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Keel RA; Schaeftlein A; Kloft C; Pope JS; Knauft RF; Muhlebach M; Nicolau DP; Kuti JL Antimicrob Agents Chemother; 2011 Jul; 55(7):3393-8. PubMed ID: 21518837 [TBL] [Abstract][Full Text] [Related]
8. Linezolid for tympanostomy tube otorrhea caused by methicillin-resistant Staphylococcus aureus and multiple drug-resistant Streptococcus pneumoniae. Isaacson G; Aronoff SC Int J Pediatr Otorhinolaryngol; 2008 May; 72(5):647-51. PubMed ID: 18321598 [TBL] [Abstract][Full Text] [Related]
9. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Gales AC; Sader HS; Andrade SS; Lutz L; Machado A; Barth AL Int J Antimicrob Agents; 2006 Apr; 27(4):300-2. PubMed ID: 16527459 [TBL] [Abstract][Full Text] [Related]
10. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. McKinnon PS; Sorensen SV; Liu LZ; Itani KM Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705 [TBL] [Abstract][Full Text] [Related]
11. Linezolid treatment of shunt-related cerebrospinal fluid infections in children. Yilmaz A; Dalgic N; Müslüman M; Sancar M; Colak I; Aydin Y J Neurosurg Pediatr; 2010 May; 5(5):443-8. PubMed ID: 20433254 [TBL] [Abstract][Full Text] [Related]
12. Bone tissue and plasma concentrations of linezolid and vancomycin in rabbits with prosthesis-related infection due to MRSA. Swoboda S; Helbig L; Kommerell M; Simank HG; Kees F; Geiss HK; Hoppe-Tichy T; Schröder K Pharmazie; 2009 Jun; 64(6):407-9. PubMed ID: 19618680 [TBL] [Abstract][Full Text] [Related]
13. [Pharmacokinetic evaluation of linezolid in patients with major thermal injuries]. Le Floch R; Arnould JF; Vinsonneau C; Hovsepian L; Stephanazzi J; Bret P; Birraux G; Lovering AM Pathol Biol (Paris); 2010 Apr; 58(2):e27-31. PubMed ID: 19854590 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. MacGowan AP J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii17-25. PubMed ID: 12730139 [TBL] [Abstract][Full Text] [Related]
15. Clearance of linezolid via continuous venovenous hemodiafiltration. Mauro LS; Peloquin CA; Schmude K; Assaly R; Malhotra D Am J Kidney Dis; 2006 Jun; 47(6):e83-6. PubMed ID: 16731287 [TBL] [Abstract][Full Text] [Related]
16. Linezolid dosage in pediatric patients based on pharmacokinetics and pharmacodynamics. Matsumoto K; Shigemi A; Takeshita A; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y J Infect Chemother; 2015 Jan; 21(1):70-3. PubMed ID: 25305808 [TBL] [Abstract][Full Text] [Related]
17. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183 [TBL] [Abstract][Full Text] [Related]
18. The CF-CIRC study: a French collaborative study to assess the accuracy of cystic fibrosis diagnosis in neonatal screening. Sermet-Gaudelus I; Roussel D; Bui S; Deneuville E; Huet F; Reix P; Bellon G; Lenoir G; Edelman A BMC Pediatr; 2006 Oct; 6():25. PubMed ID: 17018149 [TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680 [TBL] [Abstract][Full Text] [Related]